Convergence Investment Partners LLC Takes Position in Globus Medical, Inc. $GMED

Posted by Brenda Bartman on Jul 21st, 2026

Convergence Investment Partners LLC bought a new stake in Globus Medical, Inc. (NYSE:GMED – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 25,132 shares of the medical device company’s stock, valued at approximately $2,165,000.

Several other large investors also recently bought and sold shares of the business. SBI Securities Co. Ltd. raised its stake in Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares in the last quarter. Advisory Services Network LLC purchased a new position in shares of Globus Medical in the 3rd quarter worth $26,000. EverSource Wealth Advisors LLC grew its stake in shares of Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after buying an additional 197 shares in the last quarter. Larson Financial Group LLC increased its holdings in shares of Globus Medical by 83.4% in the 4th quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock worth $46,000 after buying an additional 242 shares during the last quarter. Finally, Summit Securities Group LLC bought a new stake in shares of Globus Medical in the 1st quarter worth about $48,000. Institutional investors own 95.16% of the company’s stock.

Insider Buying and Selling at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the sale, the director directly owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 18.38% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Needham & Company LLC increased their price target on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a report on Friday, May 8th. Truist Financial reduced their price objective on Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Thursday, July 16th. Wall Street Zen downgraded Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Zacks Research lowered Globus Medical from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research note on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Globus Medical has a consensus rating of “Moderate Buy” and a consensus target price of $103.75.

View Our Latest Research Report on GMED

Globus Medical Stock Performance

Shares of NYSE GMED opened at $76.23 on Tuesday. Globus Medical, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The company has a market cap of $10.35 billion, a price-to-earnings ratio of 17.73, a PEG ratio of 1.59 and a beta of 0.95. The business’s 50 day moving average price is $79.83 and its 200-day moving average price is $86.37.

Globus Medical (NYSE:GMED – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. The company had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.Globus Medical’s revenue was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Sell-side analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

About Globus Medical

(Free Report)

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.